Integrated BioPharma appoints Damon DeSantis to Board, replacing Carl DeSantis

INTEGRATED BIOPHARMA INC

Carl DeSantis resigned as Class I Director on June 20, 2022; no disagreement cited.
Damon DeSantis appointed to fill vacancy, will serve as Class I Director until 2024.
Damon is son of Carl DeSantis, a principal shareholder, and serves on boards of MacPherson's and Celsius Holdings (CELH).
Damon received a stock option for 50,000 shares at closing price on June 27, 2022, vesting quarterly through June 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.